Severe acute respiratory distress syndrome (ARDS) is a life-threatening disease with a high mortality rate. Although many therapeutic trials have been performed for improving the mortality of severe ARDS, limited strategies have demonstrated better outcomes. Recently, advanced rescue therapies such as extracorporeal membrane oxygenation (ECMO) made it possible to consider lung transplantation (LTPL) in patients with ARDS, but data is insufficient. We report a 62-year-old man who underwent LTPL due to ARDS with no underlying lung disease. He was admitted to the hospital due to influenza A pneumonia-induced ARDS. Although he was supported by ECMO, he progressively deteriorated. We judged that his lungs were irreversibly damaged and decided he needed to undergo LTPL. Finally, bilateral sequential double-lung transplantation was successfully performed. He has since been alive for three years. Conclusively, we demonstrate that LTPL can be a therapeutic option in patients with severe ARDS refractory to conventional therapies.
.
Discussion
We here describe a 62 year old male patient who underwent LTPL as a final therapeutic option for ARDS induced by influenza pneumonia that was refractory to conventional therapies. This case illustrates that in cases with no underlying lung disease or other organ failure, LTPL is a possible final therapeutic option for refractory ARDS, even in older patients. To date, some cases of severe ARDS who ultimately underwent LTPL have been reported. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Among these reported cases however, pneumonia-induced ARDS patients who were treated with LTPL are rare. [10] In addition, the cases of this type that have been reported previously were all teenagers whereas our current case report is distinct as our patient was a much older man.
LTPL has been typically conducted in patients with irreversible end-stage lung disease, such as interstitial pulmonary fibrosis or chronic obstructive pulmonary disease. [13] The recent applications of advanced life support, such as ECMO, have made it possible for patients with acute respiratory failure, such as acute deterioration from chronic lung disease or severe ARDS, to undergo LTPL. [1] However, the indications for LTPL among such patients remain controversial. Regarding ARDS, many arguments for indications for LTPL have been put forward to date [14, 15] and the main issue has been the reversibility of ARDS. Our current ARDS case also raised the question of reversibility but the LTPL could not have been delayed because his hypoxemia did not improve, even after VV-A ECMO was applied. His RV failure was not expected to have recovered if his lung had not improved. One month has elapsed at that time after the onset of pneumonia-induced ARDS. We judged that the AR- Fig. 3 . His normal chest radiograph one year after lung transplantation. DS-induced lung fibrosis, and expected ventilator-induced lung injury following continued mechanical ventilation over 2 weeks, would continue to progress and that the patient would soon die without this surgery. In our view therefore, his clinical status was irreversible. After LTPL, the pathology of his explanted lung exhibited end stage fibrosis and multifocal honeycomb changes that were consistent with fibrotic phase diffuse alveolar damage (Fig. 4) . These findings supported our clinical judgment.
Our current case is also an example of the use of ECMO therapy as a bridge to LTPL. Soon after the introduction of extracorporeal life support for respiratory failure, ECMO was not recommended as a therapy for ARDS because of its high associated mortality. [16] However, recent advances in ECMO technology have enabled the possibility of achieving a survival benefit with this intervention in patients with severe ARDS. [2, 17] Despite the many controversies surrounding it, the recent CESAR trial [17] did indicate that ECMO might improve the outcomes of patients with severe refractory hypoxemia if they did not respond to other conventional rescue therapies and could be transferred to a center that could provide this treatment. [1] Recently, ECMO therapy has been attempted as a bridge to LTPL at many centers. [12] Because the use of ECMO itself cannot guarantee recovery from the underlying lung disease, it should not be applied in any patient with a condition that is expected to be irreversible. LTPL is an effective life-saving treatment for patients with irreversible end-stage lung disease, so the use of ECMO as a bridge to LTPL could be considered acceptable in such cases. In our present case, the first ECMO therapy two weeks after intensive care unit admission was administered on the expectation that he could improve within a certain period of time. However, when we elected for a second application of ECMO because of the subsequent rapid deterioration that followed weaning from his first ECMO therapy, our decision was made under the premise that he might need LTPL as the ultimate treatment. Indeed, he had a relative contraindication for ECMO therapy i.e. prolonged mechanical ventilation for more than 7 days. However, in accordance with current international guidelines, [18] he had no organ dysfunction other than respiratory failure and no absolute contraindication, such as a precluding anticoagulation therapy. Thus, we elected for him to receive a second round of ECMO therapy.
To date, the use of LTPL to treat refractory acute respiratory failure without underlying lung disease has mostly been reported in patients with paraquat poisoning, [3, 4] posttraumatic ARDS, [6] inhalation injury, [9] acute interstitial pneumonia, [11, 12] sepsis-induced ARDS, [5] and pneumonia-induced ARDS. [10] Some instances of this intervention have been reported in patients with post-ARDS fibrosis undergoing long-term mechanical ventilation. [19] However, most of these patients were young and had no underlying illnesses.
In practice, it is difficult for physicians to wait and see how the condition of a patient will develop, especially when they are young with no previous lung diseases or serious comor- [20] There was no significant difference reported in the Fig. 4 . The pathology of his explanted lungs showed end-stage lung disease with ring fibrosis and multifocal microscopic honeycomb change consistent with fibrotic phase of diffuse alveolar damage.
survival rates at 1-year (74% versus 78%) and 3-years (65% versus 62%) after LTPL between patients with and without ECMO support. [20] That study did not include ARDS patients, but most case reports of ARDS patients treated with LTPL describe using supporting ECMO. Therefore, our current case shows similarities with previously reported ARDS patients. Taken together, previous data and our current case suggest that LTPL could represent an additional therapeutic option in properly selected patients with refractory severe ARDS.
In conclusion, LTPL bridged with ECMO was successfully carried out to achieve long-term survival in an older patient with severe ARDS that was refractory to conventional therapies. We found that if a patient suffered from life-threatening ARDS that is refractory to other rescue therapies, LTPL can represent a therapeutic option. However, the careful selection of patients without concurrent organ dysfunction or serious comorbidities should be ensured to achieve success with this approach.
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